Global /China /Healthcare /Drug Manufacturers - General /603718
chevron_leftBack
Shanghai Hile Bio-Technology Co., Ltd. logo

Shanghai Hile Bio-Technology Co., Ltd.

603718
SSE: 603718 Delayed
3.90CNY 1.3%
0.5763 USD
As of 15 June 2026, Shanghai Hile Bio-Technology Co., Ltd. has a market cap of $375.21M USD, ranking #17119 globally and #5324 in China. It ranks #1552 in the Healthcare sector, and #560 in the Drug Manufacturers - General industry.
Global Rank
17119
Country Rank
5324
Sector Rank
1552
Industry Rank
560
Key Stats
Market Cap
$375.21MUSD
2.54B CNY
Enterprise Value
$333.02MUSD
2.25B CNY
Revenue (TTM)
$27.73MUSD
187.87M CNY
EBITDA (TTM)
$8.91MUSD
60.32M CNY
Net Income (TTM)
-$45.96MUSD
-311.44M CNY
EBITDA Margin
32%
Profit Margin
-166%
PS Ratio
13.5
PB Ratio
2.8
EV/EBITDA
37.1
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Benyi Han open_in_new
Employees
366
Founded
1981
Website
hile-bio.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1.3% -2% -16% -41% -44% -42%

News

Loading...

Markets

Exchange Ticker Price
Shanghai Stock Exchange
MIC: XSHG
PRIMARY
603718
上海海利生物技术股份有限公司 Class A
ISIN: CNE1000022T4
Shares Out.:
645.223M1 Shares Float: 340.776M2
TV:
SA:
YF:
GF:
BA:
MS:
3.90 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Shanghai Hile Bio-Technology Co., Ltd.

Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry reagents, latex enhanced immune turbidimetry reagents, enzyme-linked immunosorbent products, and related diagnostic kits, including matrix metalloproteinase 3, IV collagen, adiponectin, creatine kinase isoenzyme, hepatic bile acid, cardiac troponin I, heparin binding protein, hemoglobin A1C, lipoprotein phospholipase A2, heart fatty acid binding protein, ferritin, sialoglycoside antigen, and procalcitonin kits. The Oral Tissue Repair and Regeneration Materials segment provides oral bone repair materials, implant systems, natural bone repair materials, oral restorative films, collagen-based bone repair matrices, and soft tissue repair matrices, primarily for dental implantation and maxillofacial bone defect repair. The company was founded in 1981 and is headquartered in Shanghai, China.

Similar Companies

Industry: Drug Manufacturers - General (China)
Name
Market Cap diff.
PE
$53.85B
364.89B CNY
14K%
44.9
603259
$49.64B
336.36B CNY
13K%
17.2
$28.52B
223.48B HKD
7K%
35.7
$18.8B
147.32B HKD
5K%
162.3
$16.51B
111.89B CNY
4K%
-
9926
$16.01B
125.46B HKD
4K%
-
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
203K%
38.1
JNJ
$547.28B
146K%
26.4
ABBV
$360.63B
96K%
97.4
$321.52B
256.25B CHF
86K%
19.9
AZN
$288.84B
215.59B GBP
77K%
27.6
NOVN
$274.65B
218.9B CHF
73K%
20.5
chevron_leftBack